Effect of Growth Hormone Therapy on Height Velocity in Korean Children with Idiopathic Short Stature

A Phase III Randomised Controlled Trial

Woo Yeong Chung, Han Wook Yoo, Jin Soon Hwang, Cheol Woo Ko, Ho Seong Kim, Dong Kyu Jin, Kee Hyoung Lee, Heon Seok Han, Premila Paranchothy, Byung Kyu Suh

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background/Aims: The SYNERGY (Saizen® for Your New Life and Brighter Tomorrow without Growth Deficiency) study is the first randomised multi-centre, open-label study to assess the short-term efficacy and safety of this recombinant human growth hormone (r-hGH) preparation for prepubertal children with idiopathic short stature in South Korea. Methods: The SYNERGY study (ClinicalTrials.gov NCT01746862) was conducted at 9 centres throughout South Korea between December 2012 and March 2015. The primary endpoint was difference in height velocity from baseline to 6 months in the treatment and control arms. Results: 97 children were screened; 90 were randomly assigned: 60 children to 0.067 mg/kg/day r-hGH for 12 months (treatment) and 30 children to 6 months of no treatment followed by 0.067 mg/kg/day r-hGH for 6 months (control). The 6-month mean height velocity in the treatment group increased from 5.63 cm/year (SD 1.62) to 10.08 cm/year (SD 1.92) (p < 0.0001) and from 4.94 cm/year (SD 1.91) to 5.92 cm/year (SD 2.01) (p = 0.0938) in the control group (between-group difference 3.47 cm/year, 95% CI 2.17-4.78; p < 0.0001). Adherence was > 90% throughout the study. The safety profile was consistent with that already known for r-hGH. Conclusion: Treatment with r-hGH in the SYNERGY study demonstrated a statistically significant increase in height velocity at 6 months.

Original languageEnglish
Pages (from-to)44-53
Number of pages10
JournalHormone Research in Paediatrics
Volume90
Issue number1
DOIs
Publication statusPublished - 2018 Sep 1

Fingerprint

Human Growth Hormone
Growth Hormone
Randomized Controlled Trials
Republic of Korea
Therapeutics
Safety
Growth

Keywords

  • Efficacy
  • Height velocity
  • Idiopathic short stature
  • Recombinant human growth hormone
  • Safety

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Effect of Growth Hormone Therapy on Height Velocity in Korean Children with Idiopathic Short Stature : A Phase III Randomised Controlled Trial. / Chung, Woo Yeong; Yoo, Han Wook; Hwang, Jin Soon; Ko, Cheol Woo; Kim, Ho Seong; Jin, Dong Kyu; Lee, Kee Hyoung; Han, Heon Seok; Paranchothy, Premila; Suh, Byung Kyu.

In: Hormone Research in Paediatrics, Vol. 90, No. 1, 01.09.2018, p. 44-53.

Research output: Contribution to journalArticle

Chung, Woo Yeong ; Yoo, Han Wook ; Hwang, Jin Soon ; Ko, Cheol Woo ; Kim, Ho Seong ; Jin, Dong Kyu ; Lee, Kee Hyoung ; Han, Heon Seok ; Paranchothy, Premila ; Suh, Byung Kyu. / Effect of Growth Hormone Therapy on Height Velocity in Korean Children with Idiopathic Short Stature : A Phase III Randomised Controlled Trial. In: Hormone Research in Paediatrics. 2018 ; Vol. 90, No. 1. pp. 44-53.
@article{534a6c441ce14838b6a22ee0390c00e1,
title = "Effect of Growth Hormone Therapy on Height Velocity in Korean Children with Idiopathic Short Stature: A Phase III Randomised Controlled Trial",
abstract = "Background/Aims: The SYNERGY (Saizen{\circledR} for Your New Life and Brighter Tomorrow without Growth Deficiency) study is the first randomised multi-centre, open-label study to assess the short-term efficacy and safety of this recombinant human growth hormone (r-hGH) preparation for prepubertal children with idiopathic short stature in South Korea. Methods: The SYNERGY study (ClinicalTrials.gov NCT01746862) was conducted at 9 centres throughout South Korea between December 2012 and March 2015. The primary endpoint was difference in height velocity from baseline to 6 months in the treatment and control arms. Results: 97 children were screened; 90 were randomly assigned: 60 children to 0.067 mg/kg/day r-hGH for 12 months (treatment) and 30 children to 6 months of no treatment followed by 0.067 mg/kg/day r-hGH for 6 months (control). The 6-month mean height velocity in the treatment group increased from 5.63 cm/year (SD 1.62) to 10.08 cm/year (SD 1.92) (p < 0.0001) and from 4.94 cm/year (SD 1.91) to 5.92 cm/year (SD 2.01) (p = 0.0938) in the control group (between-group difference 3.47 cm/year, 95{\%} CI 2.17-4.78; p < 0.0001). Adherence was > 90{\%} throughout the study. The safety profile was consistent with that already known for r-hGH. Conclusion: Treatment with r-hGH in the SYNERGY study demonstrated a statistically significant increase in height velocity at 6 months.",
keywords = "Efficacy, Height velocity, Idiopathic short stature, Recombinant human growth hormone, Safety",
author = "Chung, {Woo Yeong} and Yoo, {Han Wook} and Hwang, {Jin Soon} and Ko, {Cheol Woo} and Kim, {Ho Seong} and Jin, {Dong Kyu} and Lee, {Kee Hyoung} and Han, {Heon Seok} and Premila Paranchothy and Suh, {Byung Kyu}",
year = "2018",
month = "9",
day = "1",
doi = "10.1159/000491016",
language = "English",
volume = "90",
pages = "44--53",
journal = "Hormone Research in Paediatrics",
issn = "1663-2818",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Effect of Growth Hormone Therapy on Height Velocity in Korean Children with Idiopathic Short Stature

T2 - A Phase III Randomised Controlled Trial

AU - Chung, Woo Yeong

AU - Yoo, Han Wook

AU - Hwang, Jin Soon

AU - Ko, Cheol Woo

AU - Kim, Ho Seong

AU - Jin, Dong Kyu

AU - Lee, Kee Hyoung

AU - Han, Heon Seok

AU - Paranchothy, Premila

AU - Suh, Byung Kyu

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Background/Aims: The SYNERGY (Saizen® for Your New Life and Brighter Tomorrow without Growth Deficiency) study is the first randomised multi-centre, open-label study to assess the short-term efficacy and safety of this recombinant human growth hormone (r-hGH) preparation for prepubertal children with idiopathic short stature in South Korea. Methods: The SYNERGY study (ClinicalTrials.gov NCT01746862) was conducted at 9 centres throughout South Korea between December 2012 and March 2015. The primary endpoint was difference in height velocity from baseline to 6 months in the treatment and control arms. Results: 97 children were screened; 90 were randomly assigned: 60 children to 0.067 mg/kg/day r-hGH for 12 months (treatment) and 30 children to 6 months of no treatment followed by 0.067 mg/kg/day r-hGH for 6 months (control). The 6-month mean height velocity in the treatment group increased from 5.63 cm/year (SD 1.62) to 10.08 cm/year (SD 1.92) (p < 0.0001) and from 4.94 cm/year (SD 1.91) to 5.92 cm/year (SD 2.01) (p = 0.0938) in the control group (between-group difference 3.47 cm/year, 95% CI 2.17-4.78; p < 0.0001). Adherence was > 90% throughout the study. The safety profile was consistent with that already known for r-hGH. Conclusion: Treatment with r-hGH in the SYNERGY study demonstrated a statistically significant increase in height velocity at 6 months.

AB - Background/Aims: The SYNERGY (Saizen® for Your New Life and Brighter Tomorrow without Growth Deficiency) study is the first randomised multi-centre, open-label study to assess the short-term efficacy and safety of this recombinant human growth hormone (r-hGH) preparation for prepubertal children with idiopathic short stature in South Korea. Methods: The SYNERGY study (ClinicalTrials.gov NCT01746862) was conducted at 9 centres throughout South Korea between December 2012 and March 2015. The primary endpoint was difference in height velocity from baseline to 6 months in the treatment and control arms. Results: 97 children were screened; 90 were randomly assigned: 60 children to 0.067 mg/kg/day r-hGH for 12 months (treatment) and 30 children to 6 months of no treatment followed by 0.067 mg/kg/day r-hGH for 6 months (control). The 6-month mean height velocity in the treatment group increased from 5.63 cm/year (SD 1.62) to 10.08 cm/year (SD 1.92) (p < 0.0001) and from 4.94 cm/year (SD 1.91) to 5.92 cm/year (SD 2.01) (p = 0.0938) in the control group (between-group difference 3.47 cm/year, 95% CI 2.17-4.78; p < 0.0001). Adherence was > 90% throughout the study. The safety profile was consistent with that already known for r-hGH. Conclusion: Treatment with r-hGH in the SYNERGY study demonstrated a statistically significant increase in height velocity at 6 months.

KW - Efficacy

KW - Height velocity

KW - Idiopathic short stature

KW - Recombinant human growth hormone

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=85052646667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052646667&partnerID=8YFLogxK

U2 - 10.1159/000491016

DO - 10.1159/000491016

M3 - Article

VL - 90

SP - 44

EP - 53

JO - Hormone Research in Paediatrics

JF - Hormone Research in Paediatrics

SN - 1663-2818

IS - 1

ER -